Glenmark Pharma gets USFDA’s nod for Fluticasone Propionate Nasal Spray

Glenmark Pharmaceuticals has received USFDA’s approval for Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray. The company’s Fluticasone Propionate Nasal Spray USP is bioequivalent and therapeutically equivalent to the reference listed drug, Flonase Nasal Spray, 0.05 mg/spray of Haleon US Holdings LLC (NDA 020121) and will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA. 

According to IQVIA sales data for the 12-month period ending June 2026, the Flonase Nasal Spray market achieved annual sales of around $295.2 million.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in many countries.